Maugain Estelle, Sasnouski Siarhei, Zorin Vladimir, Merlin Jean-Louis, Guillemin François, Bezdetnaya Lina
Centre Alexis Vautrin, CRAN CNRS UMR 7039, Avenue de Bourgogne, 54511 Vandoeuvre-Les-Nancy Cedex, France.
Oncol Rep. 2004 Sep;12(3):639-45.
The tumoricidal effect of Foscan-mediated photodynamic therapy may involve both vessel and tumor cell destruction. The relevant importance of each mechanism seems to be defined by the time interval between photosensitizer administration and illumination (drug-light interval, DLI). Short drug-light intervals favor vascular damage due to the preferential photosensitizer accumulation in the tumor vasculature, whereas long drug-light intervals trigger direct tumor cell damage due to the dye localization in the tumor. The purpose of this study was to investigate the influence of tumor, plasma and leukocyte concentrations of Foscan at different times after photosensitizer delivery on PDT response. Both pharmacokinetic and tumor-response studies were carried out in nude mice bearing s.c. Colo26 tumors. One to 96 h after i.v. injection of 0.5 mg/kg Foscan, animals were exposed to 10 J/cm(2) 652-nm light delivered at 30 mW/cm(2). Mean tumor regrowth time was determined for each schedule of treatment and correlated to Foscan distribution in the compartments of interest at the time of illumination. PDT efficacy was greatest for irradiations performed at 6 and 12 h post Foscan injection and limited at 96 h. Unlike tumor and plasma Foscan concentrations, photosensitizer accumulation in leukocytes exhibited a good correlation with PDT efficacy. The results suggest that leukocytes could play an important role in the mechanism of PDT-induced vascular damage either by being one of the main effector compartments or by better reflecting Foscan accumulation in endothelial cells compared to plasma. The prevalence of indirect damage was highlighted by the fact that PDT efficacy was not modified by the use of a higher fluence rate of irradiation (160 mW/cm(2)), which depleted intratumor oxygen and did not restrain PDT-induced cell toxicity.
福司可林介导的光动力疗法的杀肿瘤作用可能涉及血管和肿瘤细胞的破坏。每种机制的相关重要性似乎由光敏剂给药与光照之间的时间间隔(药物-光照间隔,DLI)决定。短的药物-光照间隔有利于血管损伤,这是因为光敏剂优先在肿瘤血管系统中蓄积,而长的药物-光照间隔会引发直接的肿瘤细胞损伤,这是由于染料在肿瘤中的定位。本研究的目的是调查光敏剂给药后不同时间福司可林在肿瘤、血浆和白细胞中的浓度对光动力疗法反应的影响。在携带皮下Colo26肿瘤的裸鼠中进行了药代动力学和肿瘤反应研究。静脉注射0.5mg/kg福司可林后1至96小时,将动物暴露于以30mW/cm²的功率递送的10J/cm² 652nm光线下。确定每种治疗方案的平均肿瘤再生长时间,并将其与光照时感兴趣隔室中福司可林的分布相关联。在福司可林注射后6小时和12小时进行的照射,光动力疗法疗效最佳,而在96小时时疗效有限。与肿瘤和血浆中的福司可林浓度不同,白细胞中光敏剂的蓄积与光动力疗法疗效呈现出良好的相关性。结果表明,白细胞可能在光动力疗法诱导的血管损伤机制中发挥重要作用,要么作为主要效应隔室之一,要么与血浆相比,能更好地反映福司可林在内皮细胞中的蓄积。通过使用更高的照射通量率(160mW/cm²),耗尽肿瘤内氧气且不抑制光动力疗法诱导的细胞毒性,光动力疗法疗效未改变,这突出了间接损伤的普遍性。